Log in

Relevant bibliographies by topics / UMEC / Journal articles

To see the other types of publications on this topic, follow the link: UMEC.

Journal articles on the topic 'UMEC'

Author: Grafiati

Published: 4 June 2021

Last updated: 12 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'UMEC.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Halpin, David M. G., Mark T. Dransfield, MeiLan K. Han, et al. "The effect of exacerbation history on outcomes in the IMPACT trial." European Respiratory Journal 55, no. 5 (2020): 1901921. http://dx.doi.org/10.1183/13993003.01921-2019.

Full text

Abstract:

IMPACT, a 52-week, randomised, double-blind trial, assessed the efficacy and safety of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus FF/VI or UMEC/VI in patients with symptomatic COPD and a history of exacerbations.Subgroup analyses assessed whether the efficacy of FF/UMEC/VI versus FF/VI or UMEC/VI and UMEC/VI versus FF/VI varies according to prior exacerbation history, and the combined effects of exacerbation history and blood eosinophil counts. Three subgroups were defined: single moderate (1 moderate/no severe; n=3056 (30%)), frequent moderate (≥2 moderate/

APA, Harvard, Vancouver, ISO, and other styles

2

Marín, José M., Luis Mateos, Juan Roldán, et al. "Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT." Therapeutic Advances in Respiratory Disease 14 (January 2020): 175346662096302. http://dx.doi.org/10.1177/1753466620963021.

Full text

Abstract:

Objectives: The IMPACT trial has compared the benefit in the reduction of moderate/severe exacerbations of single inhaler triple therapy (SITT) with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) versus dual therapy with FF/VI (ICS/LABA) and UMEC/VI (LAMA/LABA) in the treatment of patients with chronic obstructive disease (COPD). This study performs a subgroup analysis of the cohort from Spain in the IMPACT study. Materials and Methods: In IMPACT, a 52-week randomized, double-blind, parallel-group, multicenter study ( N = 10,355), patients ⩾40 years of age with COPD and ⩾1 modera

APA, Harvard, Vancouver, ISO, and other styles

3

Inoue, Haruhiro, Mary Raina Angeli Fujiyoshi, Akiko Toshimori, et al. "Unified magnifying endoscopic classification for esophageal, gastric and colonic lesions: a feasibility pilot study." Endoscopy International Open 09, no. 09 (2021): E1306—E1314. http://dx.doi.org/10.1055/a-1499-6638.

Full text

Abstract:

Abstract Background and study aims Image-enhanced magnifying endoscopy allows optimization of the detection and diagnosis of lesions found in the gastrointestinal tract. Current organ-specific classifications are well-accepted by specialized endoscopists but may pose confusion for general gastroenterologists. To address this, our group proposed the Unified Magnifying Endoscopic Classification (UMEC) which can be applied either in esophagus, stomach, or colon. The aim of this study was to evaluate the diagnostic performance and clinical applicability of UMEC. Patients and methods A single-cente

APA, Harvard, Vancouver, ISO, and other styles

4

Riley, John H., Chris J. Kalberg, Alison Donald, David A. Lipson, Muhammad Shoaib, and Lee Tombs. "Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study." ERJ Open Research 4, no. 1 (2018): 00073–2017. http://dx.doi.org/10.1183/23120541.00073-2017.

Full text

Abstract:

This multicentre, randomised, double-blind, placebo-controlled, two-period crossover study assessed the effect of umeclidinium/vilanterol (UMEC/VI) on exercise capacity in patients with chronic obstructive pulmonary disease (COPD) using the endurance shuttle walk test (ESWT).Patients were randomised 1:1 to one of two treatment sequences: 1) UMEC/VI 62.5/25 µg followed by placebo or 2) placebo followed by UMEC/VI 62.5/25 µg. Each treatment was taken once daily for 12 weeks. The primary end-point was 3-h post-dose exercise endurance time (EET) at week 12. Secondary end-points included trough for

APA, Harvard, Vancouver, ISO, and other styles

5

Pascoe, Steven J., David A. Lipson, Nicholas Locantore, et al. "A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol." European Respiratory Journal 48, no. 2 (2016): 320–30. http://dx.doi.org/10.1183/13993003.02165-2015.

Full text

Abstract:

Patients with symptomatic advanced chronic obstructive pulmonary disease (COPD) who experience recurrent exacerbations are particularly at risk of poor outcomes and present a significant burden on healthcare systems. The relative merits of treating with different inhaled combination therapies e.g. inhaled corticosteroids (ICS)/long-acting β2-agonist (LABA), LABA/long-acting muscarinic antagonists (LAMA), ICS/LABA/LAMA, in this patient group are poorly understood, as is reflected in current guidelines. The InforMing the PAthway of COPD Treatment (IMPACT) study will evaluate the efficacy and saf

APA, Harvard, Vancouver, ISO, and other styles

6

Naya, Ian, Chris Compton, Afisi S. Ismaila, et al. "Preventing clinically important deterioration with single-inhaler triple therapy in COPD." ERJ Open Research 4, no. 4 (2018): 00047–2018. http://dx.doi.org/10.1183/23120541.00047-2018.

Full text

Abstract:

Clinically important deterioration (CID) is a novel composite end-point (lung function, health status, exacerbations) for assessing disease stability in patients with chronic obstructive pulmonary disease (COPD).We prospectively analysed CID in the FULFIL study. FULFIL (ClinicalTrials.govNCT02345161; randomised, double-blind, double-dummy, multicentre study) compared 24 weeks of once daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 µg with twice daily budesonide/formoterol (BUD/FOR) 400/12 μg in patients aged ≥40 years with symptomatic advanced COPD (G

APA, Harvard, Vancouver, ISO, and other styles

7

Kerwin, Edward M., Isabelle H. Boucot, Claus F. Vogelmeier, et al. "Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial." Therapeutic Advances in Respiratory Disease 14 (January 2020): 175346662092694. http://dx.doi.org/10.1177/1753466620926949.

Full text

Abstract:

Background: In chronic obstructive pulmonary disease (COPD), both the time needed for patients to gain symptom improvement with long-acting bronchodilator therapy and whether an early response is predictive of a sustained response is unknown. This study aimed to investigate how quickly meaningful symptom responses are seen in patients with COPD with bronchodilator therapy and whether these responses are sustained. Methods: Early MAXimisation of bronchodilation for improving COPD stability (EMAX) was a 24-week, double-blind, double-dummy, parallel-group trial that randomised patients to umeclid

APA, Harvard, Vancouver, ISO, and other styles

8

Halpin, David M. G., Ruby Birk, Noushin Brealey, et al. "Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses." ERJ Open Research 4, no. 2 (2018): 00119–2017. http://dx.doi.org/10.1183/23120541.00119-2017.

Full text

Abstract:

Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD) and at risk of exacerbations. However, the benefits versus side-effects of triple inhaled therapy for COPD, based on distinct patient clinical profiles, are unclear.FULFIL, a phase III, randomised, double-blind study, compared 24 weeks of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 µg using the Ellipta inhaler with twice-daily budesonide/formoterol (BUD/FOR

APA, Harvard, Vancouver, ISO, and other styles

9

Micheletto, Claudio, and Alice Sparacino. "Triple Therapy in COPD." Current Respiratory Medicine Reviews 15, no. 2 (2019): 102–11. http://dx.doi.org/10.2174/1573398x15666190314151921.

Full text

Abstract:

: Triple inhaled therapy for Chronic Obstructive Pulmonary Disease (COPD) includes an inhaled corticosteroid (ICS), a long-acting b2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) taken in combination. Triple therapy is recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) for patients who experience recurrent exacerbations despite treatment with either a dual bronchodilator or LABA/ICS combination. There is consistent evidence that the LABA/LAMA/ICS combination has significantly greater effects on trough FEV1, symptoms, quality of life, and exercise p

APA, Harvard, Vancouver, ISO, and other styles

10

Han, MeiLan K., Gerard J. Criner, Mark T. Dransfield, et al. "Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis." ERJ Open Research 7, no. 1 (2021): 00663–2020. http://dx.doi.org/10.1183/23120541.00663-2020.

Full text

Abstract:

IntroductionClinically important deterioration (CID) is a multicomponent measure for assessing disease worsening in chronic obstructive pulmonary disease (COPD). This analysis investigated the prognostic value of a CID event on future clinical outcomes and the effect of single-inhaler triple versus dual therapy on reducing CID risk in patients in the IMPACT trial.MethodsIMPACT was a phase III, double-blind, 52-week, multicentre trial. Patients with symptomatic COPD and at least one moderate/severe exacerbation in the prior year were randomised 2:2:1 to fluticasone furoate/umeclidinium/vilanter

APA, Harvard, Vancouver, ISO, and other styles

11

Hanania, Nicola, Robert Wise, Gregory Feldman, et al. "COMPARISON BETWEEN FF/UMEC/VI VS UMEC/VI AND FF/VI AND UMEC/VI VS FF/VI BASED ON BASELINE EXACERBATION HISTORY AND FEV1: SUB-ANALYSIS FROM THE IMPACT TRIAL." Chest 156, no. 4 (2019): A475—A478. http://dx.doi.org/10.1016/j.chest.2019.08.490.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Alcántara Ramos, Sonia. "Factores relacionados al sobrepeso y obesidad en pacientes atendidos en la Unidad de Medicina Complementaria del Hospital II Vitarte." Revista Peruana de Medicina Integrativa 2, no. 1 (2017): 5. http://dx.doi.org/10.26722/rpmi.2017.21.39.

Full text

Abstract:

Objetivo: Determinar los factores relacionados al diagnóstico de obesidad y sobrepeso en pacientes atendidos en la Unidad de Medicina Complementaria (UMEC) del Hospital II Vitarte durante el año 2008. Materiales y métodos: Estudio transversal. Se evaluaron características socio-demográficas (edad, sexo, procedencia), estado nutricional y comorbilidades asociadas en historias clínicas de 626 pacientes atendidos en la UMEC. Se usaron el test exacto de Fisher, la prueba de Kruskal-Wallis y un análisis de regresión logística multinomial para determinar posibles factores asociados. Resultados: Se e

APA, Harvard, Vancouver, ISO, and other styles

13

Bratton, Daniel, Benjamin Hartley, Neil Barnes, et al. "BENEFIT–RISK PROFILES OF FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) VS UMEC/VI IN PATIENTS WITH COPD: A MARKOV MODEL." Chest 158, no. 4 (2020): A1666—A1671. http://dx.doi.org/10.1016/j.chest.2020.08.1495.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

WISE, ROBERT, RALF VAN DER VALK, EMMA HILTON, et al. "TREATMENT EFFECTS OF FF/UMEC/VI VS FF/VI AND UMEC/VI IN REVERSIBLE AND NONREVERSIBLE COPD PATIENTS: ANALYSES OF THE IMPACT STUDY." Chest 154, no. 4 (2018): 729A—731A. http://dx.doi.org/10.1016/j.chest.2018.08.662.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Van Der Valk, R. J., E. C. Hilton, G. J. Criner, et al. "Effets du traitement FF/UMEC/VI versus FF/VI et UMEC/VI chez les patients BPCO réversibles et non réversibles : analyses de l’étude IMPACT." Revue des Maladies Respiratoires 36 (January 2019): A98. http://dx.doi.org/10.1016/j.rmr.2018.10.199.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

ABBOTT, CARL, EMMA HILTON, GERARD CRINER, et al. "TREATMENT EFFECTS OF FF/UMEC/VI VS FF/VI AND UMEC/VI IN COPD PATIENTS BY AIRFLOW LIMITATION SEVERITY: POST-HOC ANALYSES OF THE IMPACT STUDY." Chest 154, no. 4 (2018): 774A—775A. http://dx.doi.org/10.1016/j.chest.2018.08.698.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Véliz Arribasplata, Maria Luisa, José Eduardo Santisteban Fernández, Edith Karim López Castillo, and Betty Mayo Simón. "Descripción del costo en medicamentos en pacientes atendidos en una unidad de atención en medicina complementaria: estudio preliminar." Revista Peruana de Medicina Integrativa 2, no. 2 (2017): 140. http://dx.doi.org/10.26722/rpmi.2017.22.56.

Full text

Abstract:

Objetivo. Describir los gastos en medicamentos en los pacientes usuarios de la Unidad de MedicinaComplementaria San Juan de Lurigancho durante el periodo de enero a julio de 2009. Materiales y métodos. Estudio descriptivo. Se evaluaron las historias clínicas electrónicas de 40 pacientes atendidos en la Unidad de Medicina Complementaria (UMEC) San Juan de Lurigancho, atendidos en los meses de enero a julio del año 2009. Se calcularon los gastos por medicamentos mediante los costos unitarios proporcionados por el software de Sistemas, Aplicaciones y Productos en Procesamiento de datos (SAP), se

APA, Harvard, Vancouver, ISO, and other styles

18

Kato, Motokazu, Keisuke Tomii, Kenichi Hashimoto, et al. "The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population." International Journal of Chronic Obstructive Pulmonary Disease Volume 14 (December 2019): 2849–61. http://dx.doi.org/10.2147/copd.s226601.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Worsley, Sally, Neil Snowise, David M. G. Halpin, et al. "Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design." ERJ Open Research 5, no. 4 (2019): 00061–2019. http://dx.doi.org/10.1183/23120541.00061-2019.

Full text

Abstract:

Effectiveness studies complement conventional randomised controlled trials by providing a holistic view of treatments in the setting of usual clinical practice. We present the protocol for the ongoing INTREPID (INvestigation of TRelegy Effectiveness: usual PractIce Design; ClinicalTrials.gov identifier: NCT03467425) study, a randomised, open-label, 24-week effectiveness study of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Trelegy) delivered by the ELLIPTA inhaler versus non-ELLIPTA multiple-inhaler triple therapy in patients with chronic obstructive pulmonary disease (C

APA, Harvard, Vancouver, ISO, and other styles

20

Celi, Alessandro, Manuela Latorre, Pierluigi Paggiaro, and Riccardo Pistelli. "Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction." Therapeutic Advances in Chronic Disease 12 (January 2021): 204062232110140. http://dx.doi.org/10.1177/20406223211014028.

Full text

Abstract:

Chronic obstructive pulmonary disease (COPD) has a 3-year mortality rate up to 37%, 2–6 times higher than the general population. We present evidence supporting pharmacological therapies to improve patient life expectancy, focusing on inhaled corticosteroids (ICSs) combined with long-acting bronchodilators (LABDs). A reduction in 3-year all-cause mortality (ACM) has been shown in patients with severe COPD treated with fluticasone propionate (an ICS) and salmeterol [long-acting beta-agonist (LABA)], compared with placebo. An observational study of elderly patients with severe COPD and multiple

APA, Harvard, Vancouver, ISO, and other styles

21

Punekar, Y. S., G. Roberts, A. Ismaila, and M. O'Leary. "Cost Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Combination Therapy Among Symptomatic COPD Patients." Value in Health 17, no. 7 (2014): A595. http://dx.doi.org/10.1016/j.jval.2014.08.2053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Vallejo-Aparicio, L. A., V. F. Paly, M. Schroeder, et al. "PRS31 THE IMPACT TRIAL: COST-EFFECTIVENESS ANALYSIS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS DUAL BRONCHODILATOR THERAPY (UMEC/VI) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SPAIN." Value in Health 22 (November 2019): S878. http://dx.doi.org/10.1016/j.jval.2019.09.2521.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Mursleen, S., D. Shah, M. Schroeder, et al. "PRS44 - INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) - SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS UMEC/VI IN PATIENTS WITH COPD: COST-EFFECTIVENESS ANALYSIS FROM A SOCIETAL PERSPECTIVE IN QUEBEC." Value in Health 21 (October 2018): S411. http://dx.doi.org/10.1016/j.jval.2018.09.2438.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Hanania, Nicola A., Scott Caveney, Tedi Soule, et al. "Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials." International Journal of Chronic Obstructive Pulmonary Disease Volume 16 (June 2021): 1925–38. http://dx.doi.org/10.2147/copd.s302864.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Paly, V., M. Schroeder, A. Martin, et al. "PRS24 - INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) - SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS FF/VI AND UMEC/VI IN PATIENTS WITH COPD: HEALTHCARE RESOURCE UTILIZATION DATA AND ASSOCIATED COSTS – GERMANY." Value in Health 21 (October 2018): S407. http://dx.doi.org/10.1016/j.jval.2018.09.2418.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

HAHN, BETH, AMI BUIKEMA, LEE BREKKE, et al. "ECONOMIC IMPACT OF EARLY USE OF UMEC/VI COMPARED WITH LATER USE IN PATIENTS WITH COPD." Chest 154, no. 4 (2018): 767A—768A. http://dx.doi.org/10.1016/j.chest.2018.08.692.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Huang, Yue Hua, Qing Xie, Ming Gao, Zhe Heng Zhou, and Xu Liu. "Study on DC Bias Magnetic Properties of Transformer with Different Structures." Applied Mechanics and Materials 672-674 (October 2014): 793–98. http://dx.doi.org/10.4028/www.scientific.net/amm.672-674.793.

Full text

Abstract:

When the HVDC works in mono-polar operation or bipolar unbalanced operation, DC flows through the neutral point and causes DC bias magnetic of transformer around HVDC grounding electrode, which influences the operation security of transformers. Beside highly saturated core, it also causes the distortion of exciting current, increasing harmonics and leakage magnetic flux, and thus the losses, which in turn results in the structures of transformer overheating and insulation aging. Based on the principle of transformer DC bias magnetic and UMEC of transformer in PSCAD/EMTDC, electromagnetic trans

APA, Harvard, Vancouver, ISO, and other styles

28

Kerwin, E., C. Kalberg, D. Galkin, et al. "Escalade thérapeutique du tiotropium à UMEC/VI chez des patients BPCO modérés symptomatiques : étude randomisée de 12 semaines." Revue des Maladies Respiratoires 34 (January 2017): A172—A173. http://dx.doi.org/10.1016/j.rmr.2016.10.408.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Siler, Thomas, Gregory Feldman, Ravi Kalhan, et al. "COMPARISON BETWEEN UMEC/VI AND FF/VI BASED ON BASELINE FEV1 REVERSIBILITY: SUB-ANALYSIS FROM THE IMPACT TRIAL." Chest 156, no. 4 (2019): A470—A473. http://dx.doi.org/10.1016/j.chest.2019.08.488.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Surosky, R. T., R. Strich, and R. E. Esposito. "The yeast UME5 gene regulates the stability of meiotic mRNAs in response to glucose." Molecular and Cellular Biology 14, no. 5 (1994): 3446–58. http://dx.doi.org/10.1128/mcb.14.5.3446.

Full text

Abstract:

We reported previously that early meiotic transcripts are highly unstable. These mRNAs exhibit half-lives of approximately 3 min when expressed during vegetative growth in glucose medium and are stabilized twofold during sporulation in acetate medium. Two genes, UME2 and UME5, that regulate the stability of meiosis-specific transcripts have been identified. The wild-type UME5 gene, which has been analyzed in detail, decreases the stability of all meiotic mRNAs tested approximately twofold when expressed during vegetative growth but has no effect on the half-lives of a number of vegetative mRNA

APA, Harvard, Vancouver, ISO, and other styles

31

Surosky, R. T., R. Strich, and R. E. Esposito. "The yeast UME5 gene regulates the stability of meiotic mRNAs in response to glucose." Molecular and Cellular Biology 14, no. 5 (1994): 3446–58. http://dx.doi.org/10.1128/mcb.14.5.3446-3458.1994.

Full text

Abstract:

We reported previously that early meiotic transcripts are highly unstable. These mRNAs exhibit half-lives of approximately 3 min when expressed during vegetative growth in glucose medium and are stabilized twofold during sporulation in acetate medium. Two genes, UME2 and UME5, that regulate the stability of meiosis-specific transcripts have been identified. The wild-type UME5 gene, which has been analyzed in detail, decreases the stability of all meiotic mRNAs tested approximately twofold when expressed during vegetative growth but has no effect on the half-lives of a number of vegetative mRNA

APA, Harvard, Vancouver, ISO, and other styles

32

Slade, David, Riju Ray, Chad Moretz, et al. "MEDICATION ADHERENCE AND COPD-RELATED COSTS AMONG PATIENTS WITH COPD TREATED WITH UMECLIDINIUM/VILANTEROL (UMEC/VI) VS TIOTROPIUM (TIO)." Chest 158, no. 4 (2020): A1720—A1721. http://dx.doi.org/10.1016/j.chest.2020.08.1525.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Bums, F. M., D. M. Giolando, and J. R. Kirchhoff. "Characterization of Ceramic-Based Dual Ultramicroelectrodes by Microscopic and Electrochemical Methods." Microscopy and Microanalysis 3, S2 (1997): 1245–46. http://dx.doi.org/10.1017/s1431927600013118.

Full text

Abstract:

Recent trends directed toward the miniaturization of electrodes have produced ultramicroelectrode (UME) devices. Interest in UMEs is due to the considerable improvement in the quality of the electrochemical information that is obtained as the dimensions of the electroactive surface decreases. UMEs exhibit increased sensitivity to analytes, decreased response time, and enhanced single-to-noise. In addition, solution resistance has a decreased influence on the signal. Finally, the reduced size of UMEs allows electroanalysis in small sampling environments. As a result, UMEs have been used in appl

APA, Harvard, Vancouver, ISO, and other styles

34

Pavord, Ian, Guy Peachey, Huib Kerstjens, et al. "Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study." Journal of Allergy and Clinical Immunology 145, no. 2 (2020): AB241. http://dx.doi.org/10.1016/j.jaci.2019.12.141.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Hosking, Louise, Astrid Yeo, Joshua Hoffman, et al. "GENETIC VARIANTS DO NOT PREDICT ACUTE COPD EXACERBATIONS OR TREATMENT RESPONSE TO FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) AND ITS COMPONENTS." Chest 158, no. 4 (2020): A1800—A1801. http://dx.doi.org/10.1016/j.chest.2020.08.1568.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Slade, David, Riju Ray, Chad Moretz, et al. "UMECLIDINIUM/VILANTEROL (UMEC/VI) COMPARED WITH TIOTROPIUM (TIO) FOR TIME-TO-FIRST INPATIENT ADMISSION AMONG PATIENTS WITH COPD IN A MANAGED CARE POPULATION." Chest 158, no. 4 (2020): A1716—A1717. http://dx.doi.org/10.1016/j.chest.2020.08.1523.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Prime, David, Melanie Hamilton, and Oonagh Patmore. "CONSISTENCY OF DOSE DELIVERY OF FLUTICASONE FUROATE (FF)/UMECLIDINIUM (UMEC)/VILANTEROL (VI) ACROSS PATIENT RELEVANT INHALATION FLOW RATES FROM A DRY-POWDER INHALER (DPI)." Chest 156, no. 4 (2019): A1786. http://dx.doi.org/10.1016/j.chest.2019.08.1550.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Halpin, D. M., S. Worsley, A. S. Ismaila, et al. "INTREPID : efficacité clinique de Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) en inhalateur unique versus triples thérapies en inhalateurs multiples en pratique clinique quotidienne." Revue des Maladies Respiratoires Actualités 13, no. 1 (2021): 102–3. http://dx.doi.org/10.1016/j.rmra.2020.11.209.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Bourdin, A., D. M. Halpin, C. E. Jones, et al. "InforMing the PAthway of COPD Treatment (étude IMPACT) – Triple thérapie en un inhalateur unique (FF/UMEC/VI) comparée à FF/VI et UMEC/VI chez les patients atteints de BPCO : résultats basés sur une analyse de la région Europe de l’Ouest (Australie, Belgique, République Tchèque, Danemark, Finlande, France, Allemagne, Pays-Bas, Norvège, Pologne, Roumanie, Espagne, Suisse, Royaume-Uni)." Revue des Maladies Respiratoires 36 (January 2019): A99—A100. http://dx.doi.org/10.1016/j.rmr.2018.10.202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Hohn, Aleta A., David S. Rotstein, and Barbie L. Byrd. "Unusual Mortality Events of Harbor Porpoise Strandings in North Carolina, 1997–2009." Journal of Marine Biology 2013 (2013): 1–13. http://dx.doi.org/10.1155/2013/289892.

Full text

Abstract:

A marked increase in the frequency of harbor porpoises (Phocoena phocoena) stranded in North Carolina in 2005 was declared as an Unusual Mortality Event (UME). Strandings occurred in January through May when harbor porpoises are seasonally present. Increased stranding rates were measured relative to a threshold to determine that the UME was occurring. The threshold analysis also revealed elevated strandings during 1999, an undeclared UME year. Recovered carcasses during 1999 and 2005 accounted for 39% of 261 strandings during 1997–2009. During 2005, of 43 strandings, primary or secondary cause

APA, Harvard, Vancouver, ISO, and other styles

41

Bowdish, K. S., and A. P. Mitchell. "Bipartite structure of an early meiotic upstream activation sequence from Saccharomyces cerevisiae." Molecular and Cellular Biology 13, no. 4 (1993): 2172–81. http://dx.doi.org/10.1128/mcb.13.4.2172.

Full text

Abstract:

Diploid a/alpha Saccharomyces cerevisiae cells cease mitotic growth and enter meiosis in response to starvation. Expression of meiotic genes depends on the IME1 gene product, which accumulates only in meiotic cells. We report here an analysis of the regulatory region of IME2, an IME1-dependent meiotic gene. Deletion and substitution studies identified a 48-bp IME1-dependent upstream activation sequence (UAS). Activity of the UAS also requires the RIM11, RIM15, and RIM16 gene products, which are required for expression of the chromosomal IME2 promoter and for meiosis. Through a selection for su

APA, Harvard, Vancouver, ISO, and other styles

42

Bowdish, K. S., and A. P. Mitchell. "Bipartite structure of an early meiotic upstream activation sequence from Saccharomyces cerevisiae." Molecular and Cellular Biology 13, no. 4 (1993): 2172–81. http://dx.doi.org/10.1128/mcb.13.4.2172-2181.1993.

Full text

Abstract:

Diploid a/alpha Saccharomyces cerevisiae cells cease mitotic growth and enter meiosis in response to starvation. Expression of meiotic genes depends on the IME1 gene product, which accumulates only in meiotic cells. We report here an analysis of the regulatory region of IME2, an IME1-dependent meiotic gene. Deletion and substitution studies identified a 48-bp IME1-dependent upstream activation sequence (UAS). Activity of the UAS also requires the RIM11, RIM15, and RIM16 gene products, which are required for expression of the chromosomal IME2 promoter and for meiosis. Through a selection for su

APA, Harvard, Vancouver, ISO, and other styles

43

Komkova, Maria A., Angelika Holzinger, Andreas Hartmann, et al. "Ultramicrosensors based on transition metal hexacyanoferrates for scanning electrochemical microscopy." Beilstein Journal of Nanotechnology 4 (October 14, 2013): 649–54. http://dx.doi.org/10.3762/bjnano.4.72.

Full text

Abstract:

We report here a way for improving the stability of ultramicroelectrodes (UME) based on hexacyanoferrate-modified metals for the detection of hydrogen peroxide. The most stable sensors were obtained by electrochemical deposition of six layers of hexacyanoferrates (HCF), more specifically, an alternating pattern of three layers of Prussian Blue and three layers of Ni–HCF. The microelectrodes modified with mixed layers were continuously monitored in 1 mM hydrogen peroxide and proved to be stable for more than 5 h under these conditions. The mixed layer microelectrodes exhibited a stability which

APA, Harvard, Vancouver, ISO, and other styles

44

Donohue, James, Sally Worsley, Chang-Qing Zhu, Liz Hardaker, and Alison Church. "Efficacy and Safety of Umeclidinium/Vilanterol (UMEC/VI) Once Daily (OD) vs Fluticasone/Salmeterol Combination (FSC) Twice Daily (BD) in Patients With Moderate-to-Severe COPD and Infrequent COPD Exacerbations." Chest 146, no. 4 (2014): 73A. http://dx.doi.org/10.1378/chest.1991492.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Schroeder, M., D. Shah, S. Mursleen, et al. "PRS46 - INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) - SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS FF/VI IN PATIENTS WITH COPD: COST-EFFECTIVENESS ANALYSIS FROM A SOCIETAL PERSPECTIVE IN QUEBEC." Value in Health 21 (October 2018): S411—S412. http://dx.doi.org/10.1016/j.jval.2018.09.2440.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Paly, V., L. A. Vallejo-Aparicio, M. Schroeder, et al. "PRS25 THE IMPACT TRIAL: IS SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) COST-EFFECTIVE VERSUS DUAL THERAPY WITH INHALED CORTICOSTEROID PLUS LONG-ACTING BETA AGONIST (FF/VI) IN PATIENTS WITH COPD IN SPAIN?" Value in Health 22 (November 2019): S877. http://dx.doi.org/10.1016/j.jval.2019.09.2515.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Slade, David, Riju Ray, Chad Moretz, et al. "IMPACT OF UMECLIDINIUM/VILANTEROL (UMEC/VI) VS TIOTROPIUM (TIO), FLUTICASONE PROPIONATE/SALMETEROL (FP/SAL), AND BUDESONIDE/FORMOTEROL (B/F) ON TIME-TO-FIRST SEVERE EXACERBATION AMONG PATIENTS WITH COPD WITH HIGH COMORBIDITIES AND HIGH COSTS." Chest 158, no. 4 (2020): A1718—A1719. http://dx.doi.org/10.1016/j.chest.2020.08.1524.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Washburn, Brian K., and Rochelle Easton Esposito. "Identification of the Sin3-Binding Site in Ume6 Defines a Two-Step Process for Conversion of Ume6 from a Transcriptional Repressor to an Activator in Yeast." Molecular and Cellular Biology 21, no. 6 (2001): 2057–69. http://dx.doi.org/10.1128/mcb.21.6.2057-2069.2001.

Full text

Abstract:

ABSTRACT The DNA-binding protein Ume6 is required for both repression and activation of meiosis-specific genes, through interaction with the Sin3 corepressor and Rpd3 histone deacetylase and the meiotic activator Ime1. Here we show that fusion of a heterologous activation domain to Ume6 is unable to convert it into a constitutive activator of early meiotic gene transcription, indicating that an additional function is needed to overcome repression at these promoters. Mutations in UME6 allowing the fusion to activate lie in a predicted amphipathic alpha helix and specifically disrupt interaction

APA, Harvard, Vancouver, ISO, and other styles

49

Stott, Mike, Alistair Regan, and Daniel Fallman. "Umeå University." Interactions 9, no. 2 (2002): 37–40. http://dx.doi.org/10.1145/505103.505118.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Day, Frank. "UMEB Program." Society of Wetland Scientists Bulletin 24, no. 3 (2007): 12–13. http://dx.doi.org/10.1672/0732-9393(2007)24[12b:up]2.0.co;2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!